IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit – RGRD Law

Core Viewpoint - The ImmunityBio class action lawsuit alleges that the company and its Executive Chairman made misleading statements regarding the efficacy of its lead product, Anktiva, leading to significant stock price declines following regulatory scrutiny [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit seeks to represent purchasers of ImmunityBio securities from January 19, 2026, to March 24, 2026 [1]. - The lawsuit is titled Douglas v. ImmunityBio, Inc., and is filed in the Central District of California [1]. - Allegations include false claims about Anktiva's ability to cure cancer and misleading representations regarding its classification as a cancer vaccine [3]. Group 2: Regulatory Issues - A warning letter from the U.S. Food and Drug Administration (FDA) was issued to ImmunityBio's CEO, indicating that promotional materials misbranded Anktiva and violated federal regulations [4]. - The FDA's letter raised public health concerns, stating that the communications created a misleading impression about Anktiva's capabilities [4]. - Following the public disclosure of the FDA warning, ImmunityBio's stock price dropped by 21% [4]. Group 3: Company Background - ImmunityBio is a biotechnology company focused on developing next-generation immunotherapies, with Anktiva as its lead biologics product [2]. - The company is facing scrutiny due to the allegations of overstating the capabilities of Anktiva by its Executive Chairman and Global Scientific and Medical Officer [3].